Related Experiment Video
Updated: Feb 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer
Xiaoai Wu1, Yongzhao Xiang1, Michael R Zalutsky2
1Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Purpose:
The prostate-specific membrane antigen (PSMA) inhibitor [211At]YF2 was investigated in a Phase 0 microdose study in patients with metastatic castration resistant prostate cancer (mCRPC). The x-rays from 211At decay were used to assess biodistribution and dosimetry.
Methods:
The biodistribution of [211At]YF2 initially was evaluated in CD-1 mice and human-equivalent estimated radiation doses were calculated using Rapid 3D-RD software. Three patients with PSMA-positive metastases confirmed by [68Ga]Ga-PSMA-11 PET/CT received [211At]YF2 (29.6-44.4 MBq) intravenously. Whole-body planar imaging was performed at 1, 4, and 24 h while SPECT/CT was conducted at 4 and 24 h. Safety assessment was performed for 7 d. Volumes of interest were manually delineated to generate time-activity curves for radiation dosimetry calculation with Rapid 3D-RD software.
Results:
Preliminary human dosimetry estimates based on murine data indicated that the kidneys received the highest dose (35.14 mGy/MBq). [211At]YF2 was well tolerated with all adverse events being ≤ Grade 2. High uptake of [211At]YF2 was observed initially in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance. Even at 24 h, pronounced uptake of [211At]YF2 in metastases identified by PSMA-PET was observed in all patients with the most prominent metastasis receiving an average dose of 31.4 mGy/MBq. A kidney dose of 15.3 mGy/MBq was calculated from patient images, considerably lower than predicted from murine biodistribution-derived human dosimetry.
Conclusions:
[211At]YF2 was safely administered to mCRPC patients and metastatic lesions were clearly delineated by 211At imaging. Normal organ accumulation resulted in favorable dosimetry. Based on these results, [211At]YF2 warrants further clinical development.
Insights
The novel alpha-particle therapy agent [211At]YF2 was safely administered to metastatic castration-resistant prostate cancer patients. This study confirmed clear delineation of metastatic lesions and favorable dosimetry, supporting further clinical development of [211At]YF2.
Area of Science:
- Nuclear Medicine and Radiopharmaceutical Therapy
- Oncology and Prostate Cancer Research
- Medical Imaging and Dosimetry
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
- Prostate-specific membrane antigen (PSMA) is a validated target for mCRPC imaging and therapy.
- Alpha-particle emitters offer potent therapeutic potential due to their high linear energy transfer.
Purpose of the Study:
- To evaluate the safety, biodistribution, and dosimetry of the alpha-particle emitting PSMA inhibitor [211At]YF2 in a Phase 0 microdose study.
- To assess the feasibility of using X-rays from 211At decay for imaging metastatic lesions in mCRPC patients.
Main Methods:
- Initial biodistribution studies were conducted in CD-1 mice.
- Three mCRPC patients with PSMA-positive metastases received intravenous [211At]YF2 (29.6-44.4 MBq).
- Whole-body planar imaging and SPECT/CT scans were performed at various time points; safety and dosimetry were assessed using Rapid 3D-RD software.
Main Results:
- [211At]YF2 was well-tolerated in patients, with all adverse events being Grade 2 or lower.
- High initial uptake was observed in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance.
- Metastatic lesions were clearly visualized, with dosimetry indicating a dose of 31.4 mGy/MBq to the most prominent metastasis and a kidney dose of 15.3 mGy/MBq.
Conclusions:
- [211At]YF2 can be safely administered to mCRPC patients, enabling clear delineation of metastatic lesions.
- The observed biodistribution and dosimetry profile of [211At]YF2 are favorable for clinical application.
- These findings support the further clinical development of [211At]YF2 for mCRPC treatment.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation
Nurses can use several methods to evaluate patient outcomes. For example, oral questions can assess cognitive learning,...
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

